SCHEMBL7138274

SCHEMBL7138274

CCOC(=O)C(C)OC1C=Cc2ccccc2N1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
TSHR P16473 3/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 1/20 0.35
PIN1 Q13526 1/20 0.35
KDM4E B2RXH2 2/20 0.34
MAPT P10636 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
P2RX4 Q99571 1/20 0.34
BRD4 O60885 1/20 0.34
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17713595 0.77 P2RX4 (0.40) SMN1; SMN2TSHRALDH1A1GAAHPGD
SCHEMBL29489190 0.74 LMNA (0.38) LMNASMN1; SMN2GAAKMT2AMAPT
SCHEMBL7049313 0.74 LMNA (0.38) LMNASMN1; SMN2GAAKMT2AMAPT
SCHEMBL4698118 0.74 KDM4E (0.43) LMNASMN1; SMN2L3MBTL1TSHRALDH1A1
Hydrochloric Acid SCHEMBL29197876 0.73 LMNA (0.38) LMNASMN1; SMN2GAAKMT2AMAPT
Hydrochloric Acid SCHEMBL30920862 0.73 LMNA (0.38) LMNASMN1; SMN2GAAKMT2AMAPT
SCHEMBL29655630 0.71 P2RX4 (0.33) TSHRALDH1A1GAAKMT2AMAPT
SCHEMBL13078687 0.69 MAPT (0.40) SMN1; SMN2GAAMAPT
SCHEMBL8559657 0.68 MAPT (0.36) LMNASMN1; SMN2TSHRALDH1A1GAA
SCHEMBL11116054 0.68 MAPT (0.43) LMNASMN1; SMN2L3MBTL1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4346898-A1 METHODS FOR INHIBITING RAS Revolution Medicines, Inc. (US) 2024-04-10 EP disclosed
WO-2023175184-A1 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER FORX THERAPEUTICS AG (CH) 2023-09-21 WO disclosed
EP-4208261-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2023-07-12 EP disclosed
WO-2019117812-A1 NEAR INFRA-RED MOLECULAR PROBES FOR USE IN DIAGNOSIS OF FIBROTIC CONDITIONS AND SCREENING OF ANTI-FIBROTIC DRUGS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2019-06-20 WO disclosed
EP-3271359-A1 ISOQUINOLIDINOBENZODIAZEPINES Cellerant Therapeutics, Inc. (US) 2018-01-24 EP disclosed
EP-3212201-A1 NUCLEOSIDE KINASE INHIBITORS BCI Pharma (FR) 2017-09-06 EP disclosed
WO-2016149546-A1 ISOQUINOLIDINOBENZODIAZEPINES CELLERANT THERAPEUTICS, INC. (US) 2016-09-22 WO disclosed
WO-2016066582-A1 NUCLEOSIDE KINASE INHIBITORS BCI PHARMA (FR) 2016-05-06 WO disclosed
WO-2015123783-A1 CATHEPSIN B-TARGETING PROBES THUNDER BAY REGIONAL RESEARCH INSTITUTE (CA) 2015-08-27 WO disclosed
EP-1183255-B1 BICYCLIC POLYAMINOACID METAL COMPLEXES, METHOD FOR PREPARING SAME AND USE IN MEDICAL IMAGING GUERBET SA (FR) 2003-03-05 EP disclosed
EP-0922700-B1 Metal chelates of macrocyclic polyaminocarboxylic derivatives and their use for the diagnostic imaging GUERBET SA (FR) 2002-09-11 EP disclosed
EP-0922700-A1 Metal chelates of macrocyclic polyaminocarboxylic derivatives and their use for the diagnostic imaging GUERBET (FR) 1999-06-16 EP disclosed